Achieve Life Sciences, Inc. (ACHV)
6.49
-0.01
(-0.15%)
USD |
NASDAQ |
Oct 23, 16:00
6.48
-0.01
(-0.15%)
After-Hours: 20:00
Achieve Life Sciences Enterprise Value : 494.28M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 494.28M |
| October 22, 2026 | 495.31M |
| October 21, 2026 | 496.33M |
| October 20, 2026 | 496.33M |
| October 19, 2026 | 506.09M |
| October 16, 2026 | 482.98M |
| October 15, 2026 | 543.58M |
| October 14, 2026 | 546.67M |
| October 13, 2026 | 546.67M |
| October 12, 2026 | 552.83M |
| October 09, 2026 | 588.78M |
| October 08, 2026 | 566.18M |
| October 07, 2026 | 571.32M |
| October 06, 2026 | 549.75M |
| October 05, 2026 | 547.69M |
| October 02, 2026 | 571.32M |
| October 01, 2026 | 601.11M |
| September 30, 2026 | 658.63M |
| September 29, 2026 | 617.54M |
| September 28, 2026 | 623.70M |
| September 25, 2026 | 602.13M |
| September 24, 2026 | 631.92M |
| September 23, 2026 | 631.92M |
| September 22, 2026 | 661.71M |
| September 21, 2026 | 654.52M |
| Date | Value |
|---|---|
| September 18, 2026 | 647.33M |
| September 17, 2026 | 640.14M |
| September 16, 2026 | 589.81M |
| September 15, 2026 | 579.53M |
| September 14, 2026 | 570.29M |
| September 11, 2026 | 552.83M |
| September 10, 2026 | 575.43M |
| September 09, 2026 | 602.13M |
| September 08, 2026 | 632.95M |
| September 04, 2026 | 699.71M |
| September 03, 2026 | 681.22M |
| September 02, 2026 | 698.69M |
| September 01, 2026 | 675.06M |
| August 31, 2026 | 643.22M |
| August 28, 2026 | 659.65M |
| August 27, 2026 | 667.87M |
| August 26, 2026 | 677.12M |
| August 25, 2026 | 666.84M |
| August 24, 2026 | 643.22M |
| August 21, 2026 | 648.36M |
| August 20, 2026 | 651.44M |
| August 19, 2026 | 703.82M |
| August 18, 2026 | 600.08M |
| August 17, 2026 | 598.02M |
| August 14, 2026 | 607.27M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Anika Therapeutics, Inc. | 273.50M |
| Perspective Therapeutics, Inc. | -49.23M |
| MiMedx Group, Inc. | 451.15M |
| ProText Mobility, Inc. | 87.23M |
| ABVC BioPharma, Inc. | 31.57M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -74.77M |
| Total Expenses (Quarterly) | 74.77M |
| EPS Diluted (Quarterly) | -0.7996 |
| Earnings Yield | -23.86% |
| Normalized Earnings Yield | -17.23 |